An interventional study of osveral and Desferal in Thalassemia, Iron Overload and Transfusion Related Complications, sponsored by Hormozgan University of Medical Sciences. Completed at 1 site in Iran, Islamic Republic of. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2011-06-14.
Sponsored by Hormozgan University of Medical Sciences · Not applicable, Interventional, and Treatment
Thalassemic patients often suffer from iron overload due to frequent blood transfusion. Oral iron chelators reduce iron overload in transfusion dependent patients. The aim of this study is to compare the efficacy and safety of osveral and desferal in transfusional iron overload patients with β-Thalassemia and intermediate Thalassemia in Bandarabbas.
This is a double blinded randomized controlled trial on Efficacy and safety of Osveral and Desferal in thalassemic patients.
416 studies on the registry are indexed under Thalassemia; 67 are open to participants now.
This study's enrollment of 138 is above the median of 37 across 277 interventional studies indexed under Thalassemia.
Browse Thalassemia studies →Hormozgan University of Medical Sciences is the lead sponsor of 23 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
20 mg/kg oral osveral daily
Drug: osveral
40mg/kg desferal for 6 nights in a week subcutaneously
Drug: Desferal
receive 20 mg/kg daily orally
Also known as: deferasirox
40-50mg/Kg for 6 nights in each week subcutaneously
Also known as: Deferoxamine
Ferritin level
ferritin level in months 4 and 8 of the study
Time frame: 8 months
Hemoglobin level
hemoglobin level at months 4 and 8 off the study.
Time frame: 8 month
Drug side effects
Leuckopenia, thrombocytopenia
Time frame: 8 months
This study is completed, as verified in Jan 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hormozgan University of Medical Sciences